Stuart Cobb - 20 Feb 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Scientific Officer
Issuer ticker: NGNE
Reported as of: 20 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 18:49:39 UTC
Prior SEC filing: 15 May 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb

Key filing fact

Stuart Cobb filed Form 4 for Neurogene Inc. (NGNE) on 24 Feb 2026.

Key facts

This page summarizes Stuart Cobb's Form 4 filing for Neurogene Inc. (NGNE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Feb 2026, 18:49.

Change

Previous filing in this sequence was filed on 15 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994301 Primary reporting owner

Cobb Stuart

Relationship: Chief Scientific Officer
Address: C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Award

Transaction value: $0
Shares: +16,500
Change %: +79%
Price: $0.000000
Shares after: 37,294
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Footnote F2

Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.